MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-100 decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 19/October/2014, 8.40 am

Life-extention therapy for Males: Stem cell protein Oct-4 increases male longevity via up regulation of its target gene, 19/October/2014, 8.18 am
October 19, 2014
Inerleukin-based therapy for cancer: IL-1β suppresses the expression of Notch1 and Notch2 via up regulation of its target gene, 19/October/2014, 8.51 am
October 19, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-100 decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 19/October/2014, 8.40 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance:  It has been shown that decreasing the expression of Tau protein alleviates the pathogenic symptoms-associated with Alzheimer’s disease. This study suggests, for the first time, that MiRNA-100 decreases the phosphorylation of Tau protein and improves the pathological symptoms associated with Tau accumulation. Thus, pharmacological formulations encompassing MiRNA-100 or its activators” can be used to treat patients suffering from Alzheimer’s disease and tauopathies.

* Research cooperation

Comments are closed.